Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HST 001 in Male Pattern Hair Loss
NCT04435847Phase 1Completed
- Sponsor
- Histogen Inc.
- Start
- May 2020
- Primary completion
- Nov 2020
- Modality
- Biologic, Protein therapy
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in androgenetic alopecia (AGA) comparing HST 001 with Placebo (2 arms). Primary endpoints: Participant assessment of procedural pain at 26 Weeks, Participant assessment of pain or other treatment site responses at 26 Weeks and 3 more. Started May 2020; status: completed.
02
Drugs
HST-001
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT04435847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04435847.